SINOVAC科兴

This Saturday, SINOVAC BIOTECH LTD., in collaboration with the China Association for Vaccines, will host an academic conference focused on the topic of "Strategic Prevention and Control of Varicella and Vaccine Application." We are thrilled to welcome esteemed experts from China, the Philippines, Turkey, Chile, Indonesia, and Belarus to share their experiences and insights on varicella prevention and control. In 2022, SINOVAC BIOTECH LTD.'s varicella vaccine received World Health Organization prequalification, and in 2024, it was approved by the China National Medical Products Administration (NMPA) for use in adolescents and adults aged 13 and older. With this expansion of the approved age range, our vaccine is set to enhance varicella prevention and control, allowing more individuals to access high-quality, internationally recognized varicella vaccines. According to the World Health Organization, varicella (commonly known as chickenpox) is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a member of the herpesvirus family. There is only one serotype of VZV, with humans serving as the sole reservoir. Following the initial infection, the virus can remain dormant in neural ganglia and may reactivate in about 10-20% of cases, leading to herpes zoster (shingles), typically in individuals over 50 years of age or those who are immunocompromised. Additionally, a vaccine with a higher concentration of the virus has been developed for shingles prevention in the elderly. We look forward to an engaging and informative conference! #Varicella #Vaccines #PublicHealth #SINOVAC

Recently, officials from 13 developing countries, including Thailand, Nigeria, Uganda, and representatives from the African Union, visited SINOVAC BIOTECH LTD. to explore our advanced vaccine production process. This visit provided them with an in-depth understanding of SINOVAC BIOTECH LTD.'s commitment to global disease prevention and control, as well as our ongoing achievements in biomedicine innovation. We are proud to play a role in advancing public health through our state-of-the-art technologies and focus on continuous improvement. Together, we can enhance global health outcomes and address pressing health challenges. #PublicHealth #Vaccines #Biomedicine #SINOVAC #GlobalHealth

🌍💉 Exciting Milestone in Polio Prevention! We're thrilled to announce that SINOVAC BIOTECH LTD. has shipped its Sabin strain inactivated polio vaccine (sIPV) to Thailand, further enhancing local efforts in polio prevention and control. Our sIPV received World Health Organization pre-certification in June 2022, and we’re proud to share that the five-dose version, msIPV, has now been prequalified by World Health Organization as of September 2024. This significant achievement not only reduces immunization costs compared to single-dose alternatives, but also aims to address global vaccine shortages — ultimately increasing access to immunity for those in need. At SINOVAC BIOTECH LTD., we are committed to advancing global health initiatives, and this shipment marks another vital step in our mission to support strategies for polio eradication. Together, we can work towards a healthier future for all! #SINOVAC #PolioPrevention #Vaccines #HealthcareInnovation #GlobalHealth

🚀✨ SINOVAC BIOTECH LTD. has just concluded an incredible experience at CPHI Milan 2024! Our booth was bustling with activity, filled with engaging conversations and smiles. We were thrilled to welcome over 200 experts from the Ministry of Health, state-owned companies, and private companies who visited our booth. 🙌💼 We are eager to connect with even more industry professionals as we work together for global health and strive to eliminate human diseases through our innovative vaccines. Check out our video showcasing the energy from Milan, where we proudly formed heart shapes to represent our passion and commitment to health. ❤️ #SINOVAC #CPHI2024 #CPHI2025 #Pharmaceuticals #Networking

🌟 We are proud to have participated in the IV Clinical Research Symposium organized by Centro de Atención e Investigación Médica (#Caimed). Our Latin America Vice President of Public Affairs, Diana Milena Calderón Noreña, engaged with experts to share insights on the significant advancements and importance of BogotáBio, Colombia's vaccine production project. At SINOVAC BIOTECH LTD., we are deeply committed to enhancing healthcare in Colombia and supporting local solutions for public health. #ClinicalResearch #HealthcareInnovation #VaccineProduction #SINOVAC #BogotáBio

We are proud to have participated in the IV Clinical Research Symposium organized by CAIMED - Centro de Atención e Investigación Médica. Our Latin America Vice President of Public Affairs, Diana Milena Calderón Noreña, engaged with experts to share insights on the significant advancements and importance of BogotáBio, Colombia's vaccine production project. At SINOVAC, we are deeply committed to enhancing healthcare in Colombia and supporting local solutions for public health. #ClinicalResearch #HealthcareInnovation #VaccineProduction #SINOVAC #BogotáBio

Thrilled to announce that SINOVAC BIOTECH LTD. and Peking University People's Hospital have signed a strategic cooperation agreement! This partnership will boost our collaboration in epidemiological research and innovative drug development. The signing ceremony was attended by SINOVAC BIOTECH LTD. Chairman, president and CEO Yin Weidong and Peking University People's Hospital President Wang Jun, also a member of the National Committee of the CPPCC and an Academician of the Chinese Academy of Engineering. #Healthcare #Innovation

🌟 This October, SINOVAC BIOTECH LTD. will be attending CPHI 2024 in Milan! We’re excited to connect with our partners and showcase our latest research and advancements in the biopharmaceutical industry. Together, we'll explore how these innovations can enhance global health! In the past year, we have received additional recognition for our hand, foot, and mouth disease (#HFMD) vaccine, with positive updates from its bivalent vaccine clinical trial. Additionally, our invested anti-rabies antibodies have led to approval for market use in China, where they are now being utilized in hospitals and clinics. Join us at Stand #10D59 in Zone FDF from October 8th to 10th. We look forward to seeing you there! #CPHI #CPHIMilan #Pharma #Biomanufacturing #Innovation #HealthTech

📢 Exciting news! SINOVAC BIOTECH LTD.’s Enterovirus Type 71 Vaccine, Inlive®, is on its way to Indonesia! This is the first vaccine authorized in the country for Hand, Foot, and Mouth Disease (HFMD), caused by EV71. Since its launch in 2016, Inlive® has provided about 40 million doses in China, significantly dropping HFMD-related deaths. We are proud that this supply will bolster Indonesia's efforts against HFMD and help protect local communities. 💪🌍 #HFMD #VaccinesSaveLives #PublicHealth #SINOVAC

Recently, three studies on SINOVAC BIOTECH LTD.'s Quadrivalent Influenza Vaccine (QIV) were published in the journals Vaccine and Vaccines. These papers demonstrate that the manufacturing process of the vaccine is both stable and reliable, confirm that its safety profile is comparable to that of an already licensed QIV, and reveal that the concomitant administration of QIV and PPSV23 in adults aged 60 and older results in non-inferior immunogenicity without increasing safety risks compared to separate administration. Join us as we explore the findings and implications of this important research. #influenza #vaccine #safety